IPH5201 / AstraZeneca, Innate 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IPH5201 / AstraZeneca, Innate
2022-001903-42: Treatment with IPH5201 and durvalumab in patients with Non-Small Cell Lung Cancer IPH5201-gyel és a durvalumabbal folytatott kezelés nem kissejtes tüdőrákban szenvedő betegeknél

Not yet recruiting
2
70
Europe
IMFINZI, IPH5201, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Imfinzi
Innate Pharma SA, Innate Pharma SA
Non-Small Cell Lung Cancer Nem kissejtes tüdőrák, Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04]
 
 
MATISSE, NCT05742607: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma
Non Small Cell Lung Cancer
06/25
09/26

Download Options